Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial-Reference-Cited by-同舟云学术

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

Published:2016-01 Issue:1 Volume:17 Page:90-98
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Takashima Tsutomu,Mukai Hirofumi,Hara Fumikata,Matsubara Nobuaki,Saito Tsuyoshi,Takano Toshimi,Park Youngjin,Toyama Tatsuya,Hozumi Yasuo,Tsurutani Junji,Imoto Shigeru,Watanabe Takanori,Sagara Yoshiaki,Nishimura Reiki,Shimozuma Kojiro,Ohashi Yasuo

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Treatment of breast cancer;Hortobagyi;N Engl J Med,1998

2. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2012

3. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline;Partridge;J Clin Oncol,2014

4. Effect of chemotherapy on survival in metastatic breast cancer;Paterson;Breast Cancer Res Treat,1981

5. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens;A'Hern;Br J Cancer,1993

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial;eClinicalMedicine;2024-08

2. Effect of Liver Dysfunction on S-1 Therapy Induced Adverse Effects: A Retrospective Cohort Study;In Vivo;2024

3. Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy;Journal of Obstetrics and Gynaecology Research;2023-10-18

4. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition;Breast Cancer;2023-10-07

5. Neoadjuvant chemotherapy reduces the levels of HMGB1 and E-cadherin in patients with breast cancer;Scientific Reports;2023-09-08